*EMBARGOED All research presented at the ACG Annual Scientific Meeting is strictly embargoed until Monday, October 17, 2016 at 8:00 am EDT.
Poster 13 Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
Author Insight from Han Chen, MD, The First Affiliated Hospital of Nanjing Medical University
What’s new here and important for clinicians?
By integrating all randomized controlled trials, this meta-analysis provides reassuring evidence against the hypothesis that incretin-based therapies increase the risk of pancreatic cancer.
The incidence of pancreatic neoplasm was even lower among incretin-based groups in trials with a duration of more than 104 weeks. There was also decreased risk of pancreatic cancer within incretin groups paralleled by placebos.
Long-term follow-up periods should be applied in future randomized control trials to further investigate such potential association. Epidemiological studies are also needed for long-term surveillance if such randomized trials are absent.
What do patients need to know?
The worldwide prevalence of Type 2 Diabetes Mellitus increased the use of incretin-based drugs. However, findings among different studies have posed a dilemma of uncertainty about the association between incretin-based therapies and risk of pancreatic cancer. Our study was conducted to investigate the potential association between incretin-based drugs and pancreatic cancer risks. We found that incretin-based therapies are not associated with increase in the risk of pancreatic cancer.
Han Chen, MD, The First Affiliated Hospital of Nanjing Medical University
Media Interview Requests:
To arrange an interview with any ACG experts or abstract authors, please contact Brian Davis of ACG via email at email@example.com or by phone at 301-263-9000.